Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13563372 | 0.85 | CDK8 (0.40) | CDK8CDK19SLC6A9OPRM1OPRD1 | |
| SCHEMBL18800970 | 0.80 | SLC6A9 (0.38) | CDK8CDK19SLC6A9OPRM1OPRD1 | |
| SCHEMBL13541903 | 0.79 | OPRM1 (0.45) | CDK8CDK19OPRM1OPRD1OPRK1 | |
| SCHEMBL16883674 | 0.77 | HSD17B10 (0.51) | CDK8CDK19OPRM1OPRD1OPRK1 | |
| SCHEMBL4838402 | 0.72 | HSD17B10 (0.35) | CDK8CDK19 | |
| SCHEMBL12918587 | 0.72 | HSD17B10 (0.35) | CDK8CDK19 | |
| SCHEMBL9029374 | 0.71 | OPRL1 (0.70) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12121672 | 0.70 | OTUD7B (0.34) | — | |
| SCHEMBL12895360 | 0.68 | OTUD7B (0.31) | — | |
| SCHEMBL21216364 | 0.67 | SMN1; SMN2 (0.35) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | CDK8 967/4885CDK19 1498/4885SLC6A9 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.